| abstract |
The present invention relates to the field of drug compounds, and more particularly to novel oxazolidin-based compounds, their enantiomers, diastereoisomers, racemates and mixtures thereof, and pharmaceutically acceptable salts thereof, As a biologically active substance. The compounds of the present invention have a strong anticoagulant activity, which also does not inhibit the activity of thrombin and thus can reduce the risk of bleeding. Through pharmacokinetic experiments, the compounds of the present invention further possessed ideal metabolic characteristics, demonstrating that oral bioavailability is far superior to that of the positive control drug rivaloxazan. |